NDAINJECTIONINJECTABLE
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
DOXERCALCIFEROL (doxercalciferol) by Pfizer is 2 analog that requires metabolic activation to form the active 1α,25-(oh) 2 d 2 metabolite, which binds to the vitamin d receptor (vdr) to result in the selective activation of vitamin d responsive pathways. Approved for secondary hyperparathyroidism, chronic kidney disease. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Doxercalciferol is a vitamin D analog administered by injection that treats secondary hyperparathyroidism in patients with chronic kidney disease. It is metabolically activated to form the active vitamin D metabolite, which binds to vitamin D receptors to suppress parathyroid hormone (PTH) synthesis and secretion. The mechanism selectively activates vitamin D-responsive pathways to restore mineral-bone homeostasis in renal disease patients.
Peak
Product is in peak commercial stage post-approval; commercial teams are focused on market penetration and maintaining share against diverse competitive mechanisms in the CKD hyperparathyroidism space.
Mechanism of Action
2 analog that requires metabolic activation to form the active 1α,25-(OH) 2 D 2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways. Vitamin D and doxercalciferol have been shown to reduce PTH levels by inhibiting PTH…
Indications (2)
Worked on DOXERCALCIFEROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.